- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07553559
Avaliação de uma Ferramenta de Apoio ao Diagnóstico Baseada em Inteligência Artificial para Adultos Idosos em Cuidados Primários (INTERLACE)
Avançando a Excelência Diagnóstica para Adultos Mais Velhos Através da Inteligência Coletiva e Aprendizagem por Imitação
Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offer a promising approach to promote diagnostic excellence for older adults.
The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.
In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Alyssa M Sliwa, BA
- Número de telefone: 215-746-3080
- E-mail: alyssa.sliwa@pennmedicine.upenn.edu
Estude backup de contato
- Nome: Nicholas Bishop, BA
- E-mail: nicholas.bishop@pennmedicine.upenn.edu
Locais de estudo
-
-
Pennsylvania
-
Philadephia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
Contato:
- Clinical Research Coordinator
- Número de telefone: 215-746-3080
- E-mail: alyssa.sliwa@pennmedicine.upenn.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Clinicians
- Work in the University of Pennsylvania Health System
- Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
- Actively treat adult patients who are 65 years old or older
Patients
- 65 years of age or older
- Have an upcoming encounter with a participating primary care clinician
- Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter
Caregivers
- 18 years old or older
- Accompanying the participating patient during the encounter with the AI CDSS
- Identified by the patient as a caregiver
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Under the age of 18 years old
- Unable to provide informed consent in the opinion of the investigator
- Has a "Research Do Not Contact" status in the electronic health record
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Use of INTERLACE tool in primary care visit
All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis. |
INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility of embedding the AI CDSS into a primary care visit
Prazo: From enrollment to the end of the study interview, up to two weeks
|
Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale. |
From enrollment to the end of the study interview, up to two weeks
|
|
Feasibility of embedding the AI CDSS into a primary care visit
Prazo: From enrollment until the end of the study interview, up to two weeks
|
Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Prazo: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Prazo: From enrollment until the end of the study interview, up to two weeks
|
Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Prazo: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
Prazo: From enrollment until the end of the study interview, up to two weeks
|
Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Gary E Weissman, MD, MSPH, University of Pennsylvania
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- 852952
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .